Schedule a Free Evaluation: 919-354-3775 contact@extivita.org
  • Facebook
  • Twitter
  • Instagram
  • RSS
  • Vimeo
  • Linkedin
  • YouTube
  • Facebook
  • Twitter
  • Instagram
  • RSS
  • Vimeo
  • Linkedin
  • YouTube
  • Patient Portal
  • Register
  • Contact
Extivita - Hyperbaric Oxygen Therapy - Durham, NC
  • Home
  • Conditions We Treat
  • Therapies
    • Hyperbaric Oxygen
    • IV Therapy
    • Neurofeedback
    • PEMF
    • Supplements
    • Longevity Challenge
  • Testimonials
  • About
    • News
    • Research
    • Extivita RTP Team
Select Page

16-Hydroxycleroda-3, 13-dien-15, 16-olide inhibits the proliferation and induces mitochondrial-dependent apoptosis through Akt, mTOR, and MEK-ERK pathways in human renal carcinoma cells.

by Extivita | Mar 14, 2017 | Lymphoma

Abstract: Renal cell carcinoma (RCC) is well known that it cannot be treated with traditional chemotherapy or radiotherapy. 16-Hydroxycleroda-3,13-dien-15,16-olide (CD), isolated from Polyalthia longifolia Benth. & Hook. f. var. pendula had been reported to...

The Use of Hyperbaric Oxygen Therapy in the Treatment of Non-healing Ulcers Secondary to Graft-versus-host Disease.

by Extivita | Jul 23, 2015 | Lymphoma

Abstract: We present the case of a 69 year-old gentleman with non-healing ulcers of the bilateral medial malleoli as a result of graft-versus-host disease (GvHD). The patient discussed was diagnosed with stage IV mantle cell lymphoma. Over the course of 4 years the...

Hyperbaric oxygen preconditioning inhibits skin flap apoptosis in a rat ischemia-reperfusion model.

by Extivita | Dec 10, 2014 | Lymphoma

Abstract: Hyperbaric oxygen (HBO) improves skin flap function and inhibits partial necrosis induced by ischemia-reperfusion (I/R) injury. Our study aimed to evaluate the mechanism underlying HBO regulation of the antiapoptosis factors associated with I/R injury of...

Central retinal artery occlusion after phacoemulsification.

by Extivita | Nov 13, 2014 | Lymphoma

Abstract: To report 2 cases of central retinal artery occlusion (CRAO) that occurred within 24 hours of routine phacoemulsification cataract surgery using peribulbar anesthesia. Case 1: An otherwise well 76-year-old woman with right pseudoexfoliation syndrome and...

Primary Cutaneous γδ T-Cell Lymphoma and Hemophagocytic Syndrome.

by Extivita | Jul 9, 2014 | Lymphoma

Abstract: Primary cutaneous γδ T-cell lymphoma and hemophagocytic syndrome (HPS) is a very rare disease process with only 41 cases of this type of lymphoma published to date. We report the case of a 56-year-old woman who developed high-grade fevers and multiple...

Sequential therapy with belimumab followed by rituximab in Sjögren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.

by Extivita | Dec 21, 2013 | Lymphoma

Abstract: The overexpression of B-cell activating factor (BAFF) in mucosa-associated lymphoid tissue (MALT) may decrease the efficacy of rituximab treatment in Sjögren’s syndrome (SS). Anti-CD20 therapy was effective on marginal zone B cells, in the murine model...
« Older Entries

Search News

 

Archives

 

Contact Us

     

     

     

     

    Professional Memberships

    HBOT Member Logo
    • About Extivita
    • Extivita RTP Team
    • Patient Portal
    • Register
    • Contact
    • Policies
    • Facebook
    • Twitter
    • Instagram
    • RSS
    © 2015-2021 Extivita, LLC
    Hyperbaric Oxygen Therapy (HBOT), Nutritional IV, Neurofeedback Clinic located in Research Triangle Park, North Carolina (RTP, Raleigh, Durham, Chapel Hill).